Infection by SARS-CoV-2 with alternate frequencies of mRNA vaccine boosting

被引:13
|
作者
Townsend, Jeffrey P. [1 ,2 ,3 ,4 ,6 ]
Hassler, Hayley B. [1 ]
Dornburg, Alex [5 ]
机构
[1] Yale Sch Publ Hlth, Dept Biostat, New Haven, CT USA
[2] Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT USA
[3] Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT USA
[4] Yale Univ, Program Microbiol, New Haven, CT USA
[5] Univ N Carolina, Dept Bioinformat & Genom, Charlotte, NC USA
[6] Yale Sch Publ Hlth, Dept Biostat, 135 Coll St, New Haven, CT 06510 USA
基金
美国国家科学基金会;
关键词
BNT162b2; mRNA-1273; mRNA vaccines; SARS-CoV-2 variant evolution; updated COVID-19 vaccine; vaccination schedule; ANTIBODY-RESPONSES; DURATION; COVID-19;
D O I
10.1002/jmv.28461
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
One of the most consequential unknowns of the COVID-19 pandemic is the frequency at which vaccine boosting provides sufficient protection from infection. We quantified the statistical likelihood of breakthrough infections over time following different boosting schedules with messenger RNA (mRNA)-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech). We integrated anti-Spike IgG antibody optical densities with profiles of the waning of antibodies and corresponding probabilities of infection associated with coronavirus endemic transmission. Projecting antibody levels over time given boosting every 6 months, 1, 1.5, 2, or 3 years yielded respective probabilities of fending off infection over a 6-year span of >93%, 75%, 55%, 40%, and 24% (mRNA-1273) and >89%, 69%, 49%, 36%, and 23% (BNT162b2). Delaying the administration of updated boosters has bleak repercussions. It increases the probability of individual infection by SARS-CoV-2, and correspondingly, ongoing disease spread, prevalence, morbidity, hospitalization, and mortality. Instituting regular, population-wide booster vaccination updated to predominant variants has the potential to substantially forestall-and with global, widespread uptake, eliminate-COVID-19.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine
    Meschi, Silvia
    Matusali, Giulia
    Colavita, Francesca
    Lapa, Daniele
    Bordi, Licia
    Puro, Vincenzo
    Leoni, Bruno D.
    Galli, Claudio
    Capobianchi, Maria Rosaria
    Castilletti, Concetta
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2021, 59 (12) : 2010 - 2018
  • [32] Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
    Ali, Kashif
    Berman, Gary
    Zhou, Honghong
    Deng, Weiping
    Faughnan, Veronica
    Coronado-Voges, Maria
    Ding, Baoyu
    Dooley, Jacqueline
    Girard, Bethany
    Hillebrand, William
    Pajon, Rolando
    Miller, Jacqueline M.
    Leav, Brett
    McPhee, Roderick
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (24): : 2241 - 2251
  • [33] SARS-COV-2 MRNA vaccine-associated cutaneous vasculitis
    Erol, Vedat Bugra
    Can, Meryem
    NORTHERN CLINICS OF ISTANBUL, 2023, 10 (06) : 816 - 818
  • [34] Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals
    Grunau, Brian
    Goldfarb, DavidM.
    Asamoah-Boaheng, Michael
    Golding, Liam
    Kirkham, Tracy L.
    Demers, Paul A.
    Lavoie, Pascal M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (03): : 279 - 281
  • [35] Nonirritant concentrations for skin testing with SARS-CoV-2 mRNA vaccine
    Marcelino, Joao
    Farinha, Sofia
    Silva, Rita
    Didenko, Irina
    Proenca, Miguel
    Tomaz, Elza
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (06): : 2476 - 2477
  • [36] A case of bullous pemphigoid after the SARS-CoV-2 mRNA vaccine
    Young, J.
    Mercieca, L.
    Ceci, M.
    Pisani, D.
    Betts, A.
    Boffa, M. J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (01) : 12 - E16
  • [37] Does the SARS-CoV-2 mRNA vaccine damage the ovarian reserve?
    Yildiz, Elif
    Timur, Burcu
    Guney, Gurhan
    Timur, Hakan
    MEDICINE, 2023, 102 (20) : E33824
  • [38] Design and preclinical evaluation of a universal SARS-CoV-2 mRNA vaccine
    Qin, Jane
    Jeon, Ju Hyeong
    Xu, Jiangsheng
    Langston, Laura Katherine
    Marasini, Ramesh
    Mou, Stephanie
    Montoya, Brian
    Melo-Silva, Carolina R.
    Jeon, Hyo Jin
    Zhu, Tianyi
    Sigal, Luis J.
    Xu, Renhuan
    Zhu, Huabin
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [39] SARS-CoV-2 mRNA vaccine: Sometimes life needs a boost
    Lo, Carson Ka-Lok
    Kumar, Deepali
    TRANSPLANT INFECTIOUS DISEASE, 2023, 25 (05)
  • [40] Orbital inflammatory disease following mRNA SARS-CoV-2 vaccine
    Grunenwald, Solange
    Lethellier, Gabriel
    Imbert, Philippe
    Dekeister, Celine
    Caron, Philippe
    CLINICAL CASE REPORTS, 2022, 10 (06):